Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05020145 · ClinicalTrials.gov registry record
COVID-19 Vaccination and Breakthrough Infections Among Persons With Immunocompromising Conditions in the United States
A clinical trial, sponsored by Pfizer.
- Completed
- Registry status
- 1,277,747
- Enrollment target
NCT05020145: Completed study, sponsored by Pfizer.
NCT05020145 is a clinical trial that has completed, run by Pfizer. The registered enrollment target is 1,277,747 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05020145 has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- 1,277,747 participants
- Enrollment target
Study Summary
This retrospective study will evaluate characteristics, vaccine utilization and outcomes among subjects with immunocompromising conditions that received COVID-19 vaccination.
Primary Outcome
The incidence rate of breakthrough cases of SARS-CoV-2 infection was calculated as the number of participants who experienced the event divided by the observed time at risk and reported as incidence rate per 100 person-years. Rate of breakthrough SARS-CoV-2 infection among fully vaccinated participants was reported in this outcome measure.
Interventions
- BIOLOGICAL BNT162b2 (Tozinameran)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,277,747 participants |
| Start Date | 2021-08-25 |
| Est. Completion | 2021-12-17 |
What the finished NCT05020145 record still lists
NCT05020145 is an observational study that tracks outcomes without assigning an intervention. Its 1,277,747 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 1 intervention - of which BNT162b2 (Tozinameran) is the first listed.
NCT05020145 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05020145 about?
NCT05020145 is a clinical study titled "COVID-19 Vaccination and Breakthrough Infections Among Persons With Immunocompromising Conditions in the United States". This retrospective study will evaluate characteristics, vaccine utilization and outcomes among subjects with immunocompromising conditions that received COVID-19 vaccination.
What is the current status of trial NCT05020145?
This trial is currently completed. The enrollment target is 1,277,747 participants. The study started on 2021-08-25. Estimated completion is 2021-12-17.
What interventions are being tested in trial NCT05020145?
The interventions under investigation include: BNT162b2 (Tozinameran) (BIOLOGICAL).
Who is sponsoring clinical trial NCT05020145?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07022951 · 1,200,000 participants
The Million Anesthesia Cases Study (MACS) - a Cohort Study of Preoperative Fasting and Perioperative Outcomes
- NCT05066763 · 1,000,000 participants
Parkinson's Foundation Surveys
- NCT07075341 · 1,000,000 participants
Healthy Living BEYOND Weight Study
- NCT07224685 · 1,000,000 participants
A Study of Mayo Clinic CV Research Heart & Voice Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI